BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 577167)

  • 1. [Problems in preclinical pharmacology when deciding on suitable animal species and animal tests models].
    Hoefke W
    Arzneimittelforschung; 1977 Feb; 27(2A):223-8. PubMed ID: 577167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Animal experiments in hospitals on the subject of addicting substances].
    Olivennes A; Olivennes F
    Ann Med Psychol (Paris); 1986 Feb; 144(2):184-90. PubMed ID: 3813321
    [No Abstract]   [Full Text] [Related]  

  • 4. The inspection of drug metabolism and pharmacokinetic studies.
    Dent NJ
    Qual Assur; 1992 Jun; 1(3):230-6. PubMed ID: 1344678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methodological characteristics of the preclinical study of the safety of drug preparations for children].
    Mal'tseva LF; Muratova GP; Motovilova VG; Sirinova NA
    Farmakol Toksikol; 1988; 51(4):96-100. PubMed ID: 3191987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modern drug development by molecular- and cell-biological methods].
    Döhmer J
    ALTEX; 2001; 18(1):9-12. PubMed ID: 11248843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The predictive value for man of toxicological findings in experimental animals (author's transl)].
    Ueberberg H
    Arzneimittelforschung; 1978; 28(11a):1975-6. PubMed ID: 582528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of human drug clearance using multiexponential techniques.
    Goteti K; Brassil PJ; Good SS; Garner CE
    J Clin Pharmacol; 2008 Oct; 48(10):1226-36. PubMed ID: 18559487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correct assessment of new compounds using in vivo screening models can reduce false positives.
    Bueters TJ; Hoogstraate J; Visser SA
    Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current approaches to the development of new pharmacologically active (medicinal) substances].
    Mashkovskiĭ MD
    Vestn Akad Med Nauk SSSR; 1982; (5):9-14. PubMed ID: 7102092
    [No Abstract]   [Full Text] [Related]  

  • 12. Extrapolation from animals to man: predictions, pitfalls and perspectives.
    Ruelius HW
    Xenobiotica; 1987 Mar; 17(3):255-65. PubMed ID: 3554785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Finding the effective dose of diuretics in man (author's transl)].
    Rupp W
    Arzneimittelforschung; 1977 Feb; 27(2A):289-95. PubMed ID: 577179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulatory antibodies: challenging the drug testing paradigm.
    Bhogal N; Combes R
    Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Problems in dose finding Practical examples presented on selected series of drugs: bronchospasmolytics, pharmacology (author's transl)].
    Engelhardt A
    Arzneimittelforschung; 1977 Feb; 27(2A):272-7. PubMed ID: 577174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early clinical evaluation in man: the buck stops here.
    Lemberger L
    Xenobiotica; 1987 Mar; 17(3):267-73. PubMed ID: 3577204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.
    Rishton GM
    Curr Opin Chem Biol; 2008 Jun; 12(3):340-51. PubMed ID: 18328272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems.
    Dixit R; Coats S
    IDrugs; 2009 Feb; 12(2):103-8. PubMed ID: 19204884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Open Field Test: reinventing the wheel.
    Stanford SC
    J Psychopharmacol; 2007 Mar; 21(2):134-5. PubMed ID: 17329288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.